IBS-trained therapists are hard to find. That’s why we developed the first prescription-only, FDA-cleared digital therapeutic that delivers gut directed cognitive behavioral therapy for IBS. Over 60% of patients treated with Mahana IBS in a clinical trial reported a clinically meaningful improvement in IBS symptom severity and saw durable effects for up to a year after their 90-day use.
Sign up to receive your free welcome pack:
The efficacy and safety of Mahana IBS was demonstrated in the ACTIB trial of 558 adult patients with refractory IBS. Mahana helped nearly 2 in 3 people in a clinical trial.1,2
Give patients the first FDA-cleared digital therapy shown in clinical trials to reduce symptom severity.
Sign up today and begin prescribing the first FDA-cleared digital therapeutic for IBS symptom relief.
Mahana’s cognitive behavioral therapy is gut-directed psychotherapy (GDP) that improves IBS symptom severity by targeting the cognitive factors known to drive symptoms. CBT is the most rigorously tested psychological treatment for IBS.
Mahana enables you to empower all IBS patients with a treatment that has no known side effects.
The gut-brain axis is a bidirectional communication system that links intestinal functions with the emotional and cognitive centers of the brain.
Be on the leading-edge with providers who understand the importance of using innovative tools to improve patient outcomes, like FDA-cleared digital therapeutics.
Explaining to patients the benefits of using Mahana IBS is fast and simple.
Our Patient FAQ sheet helps explain the brain-gut connection and allows patients to learn about the benefits of gut-directed CBT using Mahana IBS.
Mahana Care is also available for your patients to provide added encouragement, support and address your patients questions related to their use of Mahana IBS.
Mahana IBS' gut directed CBT model helps patients develop skills in 10 key areas over the course of their 90-day prescription to reduce severity of symptoms.
Patients have more information at their fingertips than ever before. That’s why it’s imperative for physicians to anticipate and understand consumer health trends.
Mahana IBS is the first and only FDA cleared digital IBS treatment. With Mahana IBS, physicians can be confident they are prescribing an efficacious and safe digital health treatment
In 2021, the number of people using digital therapeutics is expected to reach 44 million worldwide. Almost double the number of users in 2020.4
We're working with leaders in gastroenterology to ensure patient and provider have the tools they need for IBS treatment.
Hazel Everitt, Ph.D, FRCGP
University of Southampton, GP & Professor of Primary Care Research
Emeran Mayer, M.D.
Director, G. Oppenheimer Center for Neurobiology of Stress and Resilience (CNSR)
Jasmine Zia, M.D.
Swedish Medical Center, Gastroenterologist
Rona Moss-Morris, Ph.D
King's College London, Head of Psychology Department, Institute of Psychiatry, Psychology & Neuroscience
Mahana IBS provides a personalized, clinically validated and FDA-cleared treatment that is available for your patients to use anytime, anywhere.
Good therapists with gut directed CBT expertise are hard to find, and IBS case workloads can take up significant clinical time.